Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $153718.0.

  • Iradimed's Gains from Investment Securities fell 8938.79% to $153718.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 1970.22%. This contributed to the annual value of $6.5 million for FY2024, which is 2167.75% up from last year.
  • Iradimed's Gains from Investment Securities amounted to $153718.0 in Q3 2025, which was down 8938.79% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Gains from Investment Securities registered a high of $2.8 million during Q2 2024, and its lowest value of -$313722.0 during Q4 2021.
  • For the 5-year period, Iradimed's Gains from Investment Securities averaged around $946935.3, with its median value being $807386.0 (2021).
  • In the last 5 years, Iradimed's Gains from Investment Securities tumbled by 21012.77% in 2021 and then surged by 40420.66% in 2022.
  • Over the past 5 years, Iradimed's Gains from Investment Securities (Quarter) stood at -$313722.0 in 2021, then skyrocketed by 404.21% to $954363.0 in 2022, then rose by 27.37% to $1.2 million in 2023, then soared by 69.06% to $2.1 million in 2024, then plummeted by 92.52% to $153718.0 in 2025.
  • Its Gains from Investment Securities stands at $153718.0 for Q3 2025, versus $2.2 million for Q2 2025 and $116297.0 for Q1 2025.